Amylin-Based Therapies in Obesity Management

Activity Description

Amylin-based therapies represent one of the most active frontiers in obesity pharmacotherapy research, yet most clinicians remain unfamiliar with the biology supporting amylin’s potential use in weight loss, the rapidly expanding pipeline, and the emerging trial evidence. In this concise Top 10 activity, expert faculty answer the questions clinicians are asking most, from amylin’s role in satiety, gastric emptying, and glucose regulation and how it differs from GLP-1, to potential integration into the therapeutic paradigm. Through a practical, question-driven format, the program reviews clinical trial data for amylin analogues, dual amylin and calcitonin receptor agonists, and combination and unimolecular approaches and explores patient selection, tolerability, counseling, and individualized management, preparing clinicians to integrate these agents as they approach clinical availability.

Target Audience

This educational activity will address identified knowledge and practice gaps among primary care, internal medicine, endocrinology, and diabetology MDs, NPs, and PAs.

Educational Objectives 

After completing this activity, the participant should be better able to:

• Explain the pathophysiology of amylin in energy regulation, including appetite control, gastric emptying, glucose homeostasis, and interactions with other satiety hormones (eg, glucagon-like peptide-1 [GLP-1])
• Describe the clinical profiles and trial evidence for emerging amylin-based therapies
• Evaluate where amylin-based therapies may be considered in individualized obesity management

Agenda

Introduction

Unmet Need: Variable patient response to existing obesity therapies creates demand for mechanistically distinct options 

New Frontiers: Amylin-based therapies are expanding the obesity treatment landscape beyond incretin approaches 

Why Now: Multiple agents approaching regulatory approval, robust clinical trial data, and evolving treatment paradigms

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Reciprocity Statement

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal. 

Integritas Contact Information

For more information about this activity, please contact Integritas Communications at info@exchangecme.com. 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Domenica M. Rubino, MD

• Consulting Fees: AbbVie Inc., AstraZeneca, Boehringer Ingelheim, Cytoki, Eli Lilly, Ferring, Neurocrine, Novo Nordisk, Pfizer Inc., Regeneron, Roche, Shionogi, Tern, Zealand
• Speakers' Bureau: Novo Nordisk
• Contracted Research: AbbVie Inc., Amgen, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Pfizer Inc.
• Stocks: AbbVie Inc.

The Integritas planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.